Do newer type 2 diabetes therapies affect CV outcomes? Results from the first two studies

Gadsby, Roger
December 2013
Diabetes Digest;2013, Vol. 12 Issue 4, p174
The article presents a study of 5380 people having type 2 diabetes with recent acute cardiovascular episode. The primary outcome was composite of death from non-fatal stroke, non-fatal myocardial infarction and cardiovascular causes. A total of 316 of the end points occurred in the placebo group and 305 in the alogliptin, showing no signal for increased cardiovascular disease (CVD) ischaemic risk.


Related Articles

  • What is the next treatment step in people with type 2 diabetes and poor glycaemic control despite optimised basal insulin? Hadley-Brown, Martin; Vora, Jiten // Diabetes Digest;2014, Vol. 13 Issue 4, p196 

    The article discusses the study "Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes," published by M. Diamant and colleagues in the 2014 issue of the journal "Diabetes Care." Topics covered include the administration of twice-daily exenatide...

  • S axagliptin and Metformin in Fixed Combination for the Treatment of Type 2 Diabetes in Adults. Minze, Molly G.; Klein, Mary S.; Terrell, Brian T. // Clinical Medicine Insights: Endocrinology & Diabetes;2013, Issue 6, p15 

    Type 2 diabetes affects millions of people worldwide and significantly contributes to morbidity and mortality of those affected by it. Current guidelines recommend individualized treatment regimens following first line metformin therapy. Saxagliptin, a dipeptidyl-peptidase 4 inhibitor, provides...

  • Diabetes and Cardiovascular Risk: Are Dipeptidyl Peptidase-4 Inhibitors Beneficial? Howard, Patricia A. // Hospital Pharmacy;Sep2014, Vol. 49 Issue 8, p697 

    Cardiovascular (CV) disease is a major cause of morbidity and mortality in patients with diabetes. Whereas the link between glycemic control and reducing microvascular disease is firmly established, the evidence for macrovascular risk reduction remains unclear. Despite a host of available drugs...

  • Liraglutide in Adults with Type 2 Diabetes: Global Perspective on Safety, Efficacy and Patient Preference. Yabe, Daisuke; Seino, Yutaka // Clinical Medicine Insights: Endocrinology & Diabetes;2011, Issue 4, p47 

    Incretin-based therapies have been gaining much attention recently as a new class of therapeutics for type 2 diabetes worldwide. Among them, glucagon-like peptide-1 receptor agonist liraglutide has been rapidly increasing its global usage. Once daily injection of liraglutide significantly...

  • Treatment burden: An overlooked aspect of diabetes management. Gadsby, Roger // Diabetes Digest;2014, Vol. 13 Issue 4, p182 

    The article discusses the concept of treatment burden in managing diabetes as of December 2014. Topics covered include the findings of the study "Effect of patients' risks and preferences on health gains with plasma glucose level lowering in type 2 diabetes," by S. Vijan and colleagues in the...

  • CARDIOVASCULAR OUTCOME STUDIES: PRESENT AND FUTURE IN DIABETES. Shestakova, Ekaterina // Problemy Endokrinologii;2017 Supplement, p7 

    Cardiovascular disease is one of the most common diabetes-associated complications. Before 2008 almost all randomized controlled studies were «glucocentric», concentrating on the glycaemic eff ect of antidiabetic drugs. In 2008 paradigm was changed to look for cardiovascular complications...

  • Antihyperglycaemics: prescribing rate unchanged by rosiglitazone warning.  // Reactions Weekly;12/12/2009, Issue 1282, p5 

    The article discusses research being done on overall utilisation of antihyperglycaemics in the U.S. Military Health System. It references the study "Temporal Trends in Anti-Diabetes Drug Use in Tricare Following Safety Warnings in 2007 About Rosiglitazone," by K. A. Stewart, published in the...

  • Gliptins for Type 2 diabetes--should we be excited? Bryant, Linda // Journal of Primary Health Care;Jun2014, Vol. 6 Issue 2, p163 

    The article focuses on the potential of gliptins such as sitagliptin and saxagliptin in managing hyperglycemia in people with type 2 diabetes and its complications. Topics covered include information about the incretin system, common side effects, and some precautions on the use of sitagliptin...

  • Prescription Pattern of Antihypertensive Agents in T2DM Patients Visiting Tertiary Care Centre in North India. Dhanaraj, Ethiraj; Raval, Amit; Yadav, Rajbharan; Bhansali, Anil; Tiwari, Pramil // International Journal of Hypertension;2012, p1 

    Background. Hypertension management is of a paramount importance in diabetic patients for cardiovascular risk reduction. Aim. To evaluate prescribing pattern of antihypertensive in T2DM (type 2 diabetes) patients and compare with existing recent guidelines. Methods. A cross-sectional study...

  • Management & prevention of type 2 diabetes. Gadsby, Roger // Diabetes Digest;2015, Vol. 14 Issue 3, p122 

    A review of the article "Incretin-based medications for type 2 diabetes: an overview of reviews," by J. M. Gamble and colleagues, which appeared in the journal "Diabetes, Obesity and Metabolism" in 2015, is presented.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics